Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 731 to 740 of 1447 total matches.
Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004 (Issue 1178)
, New Rochelle, NY 10801 A Nonprofit Publication
Vol. 46 (Issue 1178)
March 15, 2004
EDITOR: Mark ...
The fixed-dose combination of olanzapine and fluoxetine (Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (Zyprexa), which is mainly used as an antipsychotic (Medical Letter 2003; 45:102), is FDA-approved for treatment of acute manic episodes and for maintenance treatment of bipolar disorder. Fluoxetine alone (Prozac, and others), which is mainly used as an antidepressant (Medical Letter 2003; 45:93), has no specific approval for use in bipolar...
Folic Acid Supplementation to Prevent Neural Tube Defects
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004 (Issue 1177)
Publication
Vol. 46 (Issue 1177)
March 1, 2004
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti ...
Many women of child-bearing age now take folic acid supplements of 400 ╡g per day to prevent neural tube defects in their offspring (Medical Letter 1998; 40:75). An FDA advisory committee has recommended development of a combination tablet containing an oral contraceptive and 400 ╡g of folic acid. A recent editorial in the New England Journal of Medicine suggested that folic acid doses should be higher (NJ Wald, N Engl J Med 2004; 350:101).
Sildenafil for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004 (Issue 1177)
Vol. 46 (Issue 1177)
March 1, 2004
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti, M.D ...
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction (Medical Letter 1998; 40:51).
An Injectable Hyaluronic Acid (Restylane) for Wrinkles
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004 (Issue 1177)
by The Medical Letter, Inc. 1000 Main Street, New Rochelle, NY 10801 A Nonprofit Publication
Vol. 46 (Issue ...
An injectable gel of hyaluronic acid (Restylane) has been approved by the FDA for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Manufactured by Q-Med AB, a Swedish company, it has been used outside the US since 1996.
Drugs for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004 (Issue 1176)
Publication
Vol. 46 (Issue 1176)
February 16, 2004
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna ...
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
Is Effexor More Effective than an SSRI?
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004 (Issue 1176)
. 1000 Main Street, New Rochelle, NY 10801 A Nonprofit Publication
Vol. 46 (Issue 1176)
February 16 ...
Venlafaxine (Effexor, Effexor XR - Wyeth), an antidepressant that inhibits both norepinephrine and serotonin reuptake, was first approved by the FDA in 1993. It has been used mainly as a second-line agent for patients who have not responded to a selective serotonin reuptake inhibitor (SSRI). Some Medical Letter consultants have had the clinical impression that venlafaxine is more effective than an SSRI, particularly for patients with severe, classic depression (melancholia), and believe it should be considered a first-line drug (Treatment Guidelines from the Medical Letter 2003, 1:69). Is...
Seasonale
The Medical Letter on Drugs and Therapeutics • Feb 02, 2004 (Issue 1175)
. 1000 Main Street, New Rochelle, NY 10801 A Nonprofit Publication
Vol. 46 (Issue 1175)
February 2 ...
Seasonale (Barr), the first "extended-cycle" oral contraceptive, is now available in the US for pregnancy prevention. Active tablets containing 30 ╡g of ethinyl estradiol and 0.15 mg of levonorgestrel are taken for 84 consecutive days, followed by 7 days of inactive tablets, allowing for withdrawal bleeding only four times a year. Other combination oral contraceptives are dispensed as 21 days of active tablets and 7 days of placebo or no tablets, resulting in 13 withdrawal bleeding episodes each year.
Emergency Contraception OTC
The Medical Letter on Drugs and Therapeutics • Feb 02, 2004 (Issue 1175)
, New Rochelle, NY 10801 A Nonprofit Publication
Vol. 46 (Issue 1175)
February 2, 2004
EDITOR: Mark ...
An FDA Advisory Committee has recommended over-the-counter (OTC) marketing of Plan B (Barr), an emergency contraceptive "pill pack" that contains two 0.75-mg tablets of levonorgestrel to be taken 12 hours apart (Medical Letter 2000; 42:10). Plan B is one of two FDA-approved products for this indication. The Preven Emergency Contraceptive Kit (Medical Letter, 40:102, 1998) includes four tablets, each containing 0.25 mg of levonorgestrel and 50 ╡g of ethinyl estradiol; these are taken 2 at a time 12 hours apart (the "Yuzpe regimen") and are available only by...
Daptomycin (Cubicin) for Skin and Soft Tissue Infections
The Medical Letter on Drugs and Therapeutics • Feb 02, 2004 (Issue 1175)
by The Medical Letter, Inc. 1000 Main Street, New Rochelle, NY 10801 A Nonprofit Publication
Vol. 46 (Issue ...
Daptomycin (Cubicin - Cubist), a cyclic lipopeptide (a new class of antibiotics), has been approved by the FDA for intravenous (IV) treatment of complicated skin and skin structure infections. It is being promoted as a once-daily bactericidal alternative to vancomycin (Vancocin, and others) for methicillin-resistant Staphylococcus aureusinfections.
Lasik and Its Alternatives: An Update
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004 (Issue 1174)
10801 A Nonprofit Publication
Vol. 46 (Issue 1174)
January 19, 2004
EDITOR: Mark Abramowicz, M.D ...
Since the last Medical Letter article on surgical correction of refractive errors (Volume 41, page 122, 1999), some new techniques have been tried and new results have been reported.